Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier. (October 2015)

• Record Type: Journal Article
• Authors: Di Gioia, Sante; Trapani, Adriana; Castellani, Stefano; Carbone, Annalucia; Belgiovine, Giuliana; Craparo, Emanuela Fabiola; Puglisi, Giovanni; Cavallaro, Gennara; Trapani, Giuseppe; Conese, Massimo
• Is Part Of: Pulmonary pharmacology & therapeutics. Volume 34(2015:Oct.)
• Page Start: 8
• Page End: 24
• Publication Date: 2015-10
• Subjects: Asthma -- Cystic fibrosis -- Lung cancer -- Mucolytics -- Poly(ethylene glycol) -- Sputum; Polyethyleinimine (PubMed CID: 9033) -- Poly-l-lysine (PubMed CID: 53628747) -- Ethylene glycol (PubMed CID: 174) -- Chitosan (PubMed CID: 71853) -- PAMAM G0 dendrimer (PubMed CID: 4140276) -- N-(1-(2, 3-Dioleyloxy)propyl)-N, N, N-trimethylammonium chloride (PubMed CID: 6438350) -- 1, 2-Dioleoylphosphatidylethanolamine (PubMed CID: 6437083) -- N-acetylcystein (PubMed CID: 12035) -- 1, 2-Dioctadecanoyl-sn-glycero-3-phosphoethanolamine (PubMed CID: 102547); Respiratory organs -- Diseases -- Chemotherapy -- Periodicals; 615.7205
• DOI: 10.1016/j.pupt.2015.07.003
• Languages: English
• ISSNs: 1094-5539

Abstract

Abstract: Gene therapy, i.e. the delivery and expression of therapeutic genes, holds great promise for congenital and acquired respiratory diseases. Non-viral vectors are less toxic and immunogenic than viral vectors, although they are characterized by lower efficiency. However, they have to overcome many barriers, including inflammatory and immune mediators and cells. The respiratory and airway epithelial cells, the main target of these vectors, are coated with a layer of mucus, which hampers the effective reaching of gene therapy vectors carrying either plasmid DNA or small interfering RNA. This barrier is thicker in many lung diseases, such as cystic fibrosis. This review summarizes the most important advancements in the field of non-viral vectors that have been achieved with the use of nanoparticulate (NP) systems, composed either of polymers or lipids, in the lung gene delivery. In particular, different strategies of targeting of respiratory and airway lung cells will be described. Then, we will focus on the two approaches that attempt to overcome the mucus barrier: coating of the nanoparticulate system with poly(ethylene glycol) and treatment with mucolytics. Our conclusions are: 1) Ligand and physical targeting can direct therapeutic gene expression in specific cell types in the respiratory tract; 2) Mucopenetrating NPs are endowed with promising features to be useful in treating respiratory diseases and should be now advanced in pre-clinical trials. Finally, we discuss the development of such polymer- and lipid-based NPs in the context of in vitro and in vivo disease models, such as lung cancer, as well as in clinical trials.